AKBA Q3 2024 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M-11.0% YoY

Gross Profit

$23M62.2% margin

Operating Income

-$13M-33.4% margin

Net Income

-$20M-53.5% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

-14.3%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$207M

Total Liabilities

$258M

Stockholders' Equity

-$50M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$42M	-11.0%
Gross Profit	$23M	$24M	-3.2%
Operating Income	-$13M	-$13M	+4.1%
Net Income	-$20M	-$14M	-38.3%

Revenue Segments

Product

$36M95%

License Collaboration And Other Revenue

$2M5%